SCHEMBL23717440

SCHEMBL23717440

CC(C)N1CC(c2ccccn2)NC1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.39
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
ALDH1A1 P00352 6/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 2/20 0.38
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
GSK3B P49841 1/20 0.38
KDM4E B2RXH2 5/20 0.36
HPGD P15428 2/20 0.36
TSHR P16473 2/20 0.36
MEN1 O00255 1/20 0.36
GFER P55789 2/20 0.36
OPRK1 P41145 2/20 0.36
HSD17B10 Q99714 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
GAA P10253 1/20 0.35
CASP1 P29466 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15743929 0.80 ALDH1A1 (0.41) DDB1CRBNALDH1A1KMT2AMAPT
SCHEMBL13413242 0.77 ALDH1A1 (0.40) DDB1CRBNALDH1A1KMT2AMAPT
SCHEMBL13394550 0.77 GSK3B (0.41) DDB1CRBNALDH1A1KMT2AMAPT
SCHEMBL20780438 0.76 KMT2A (0.42) KMT2ANPC1MEN1SMN1; SMN2LMNA
SCHEMBL20780479 0.74 L3MBTL1 (0.36) DDB1CRBNALDH1A1GSK3BKDM4E
SCHEMBL20794437 0.73 CYP2C19 (0.46) KMT2ARAB9AKDM4ETSHRMEN1
SCHEMBL22222452 0.72 SMN1; SMN2 (0.41) ALDH1A1KMT2AGSK3BKDM4EHPGD
SCHEMBL24783326 0.70 GSK3B (0.41) DDB1CRBNALDH1A1KMT2AMAPT
SCHEMBL20993365 0.68 ALDH1A1 (0.44) DDB1CRBNALDH1A1KMT2AMAPT
SCHEMBL20993213 0.68 ALDH1A1 (0.44) DDB1CRBNALDH1A1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210290623-A1 METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) 2021-09-23 US disclosed
US-20210236442-A1 METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210236442-A1 METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES IAPP, SLC5A2, SLC2A2 KDM5A 3223/4885DDB1 2305/4885CRBN 3859/4885
US-20210290623-A1 METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS HMGCR, PCSK9, FABP3 KDM5A 3071/4885DDB1 1441/4885CRBN 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.